



28 October 2025

ASX ANNOUNCEMENT

New US Clinical Trial Contract

CONNEQT Health Limited (ASX: CQT) (“CONNEQT” or “the Company”) is pleased to announce that it has been awarded a new Phase 2b clinical trial contract with a privately owned U.S.-based Biopharmaceutical company focused on developing therapies for the treatment of hypertension and other serious cardiovascular diseases.

Trial Contract Overview

The trial will support the development and evaluation of innovative treatments for hypertension and cardiovascular disease. It is expected to commence in Q4 2025 and will run for approximately nine months across 30 sites in the United States.

Under the agreement, CONNEQT will provide a full suite of vascular assessment and monitoring platforms, including 30 SphygmoCor® XCEL systems and 60 Oscar 2 ABPM systems. The Company will also provide setup, training, support and data management services for collecting and analysis of important endpoints of the study for all participating clinical sites.

The contract has a total value of approximately A\$1.1 million (US\$716,000), inclusive of equipment leasing, operational support and data-management services. Revenue will be recognised progressively over the duration of the trial.

The trial leverages the Company’s proprietary non-invasive vascular biomarker measurement solutions to enable precise endpoint reliability and superior data integrity.

Craig Cooper, CEO, CONNEQT Health commented:

“This new U.S. trial contract represents another important milestone in expanding our clinical and pharmaceutical partnerships. It showcases the confidence biopharma leaders are placing in CONNEQT’s technology to deliver the precision and scalability required for next-generation cardiovascular studies.”

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

C O N N E Q T
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Sydney NSW 2000
Australia

+61 2 9874 8761

ASX ANNOUNCEMENT



For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").

C O N N E Q T
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Sydney NSW 2000
Australia

+61 2 9874 8761